Infectious Disease Full List Download Inflammation and Infectious Disease Full List Download

It is important to diagnose the infectious disease even before it becomes serious. The traditional pathogen-detection methods, such as culture, have established their credibility over time, they are often slow and relatively insensitive. In addition, there are several emerging infectious diseases (ID) such as dengue fever, zika virus, corona virus and so on are need to be diagnosed immediately to prevent the outbreak. Immunodiagnostics show great promise than the traditional methods used in clinical diagnosis. GENEMEDI developed the antigens and antibodies for rapid kit such as ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT to detect the different types of infectious disease.



Influenza A (flu A)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
					Influenza A (nucleoprotein (NP))		Influenza A (nucleoprotein (NP)) antigen	
					antibodies binding, Immunogen in	GMP-IVD-P001-Tg001-Ab01;	binding, ELISA validated as capture antibody	
CMD IVD	Influenza A (flu	nuelconretein		GMP-IVD-P001-Tg001-Ag01:	Sandwich Elisa, lateral-flow tests, and	GMP-IVD-P001-Tg001-Ab02:	and detection antibody. Pair recommendation	
GMP-IVD-	,	u nucleoprotein (NP)	Flu	Recombinant Influenza A (flu	other immunoassays as control material	Anti-Influenza A (flu A)	with other Influenza A (nucleoprotein (NP))	=
P001-Tg001	1-Tg001 A)			A) nucleoprotein (NP) Protein	in nucleoprotein (NP) level test of	nucleoprotein (NP) mouse	antibodies in nucleoprotein (NP) level test of	
					Infectious disease (Flu) and related	monoclonal antibody (mAb)	Infectious disease (Flu) and related syndrome	
					syndrome evaluation.		evaluation.	

For inquiry please click here to contact us or send email to support@genemedi.net

Influenza B (Flu B)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order			
					Influenza B (nucleoprotein (NP))		Influenza B (nucleoprotein (NP)) antigen				
			Flu	nucleopratein				antibodies binding, Immunogen in	GMP-IVD-P002-Tg001-Ab01;	binding, ELISA validated as capture antibody	
GMP-IVD-	Influenza B					GMP-IVD-P002-Tg001-Ag01:	Sandwich Elisa, lateral-flow tests, and	GMP-IVD-P002-Tg001-Ab02:	and detection antibody. Pair recommendation		
				Flu	Recombinant Influenza B (Flu	other immunoassays as control material	Anti-Influenza B (Flu B)	with other Influenza B (nucleoprotein (NP))	=		
P002-Tg001	(Flu B)				B) nucleoprotein (NP) Protein	in nucleoprotein (NP) level test of	nucleoprotein (NP) mouse	antibodies in nucleoprotein (NP) level test of			
				Infectious disease (Flu) and related	monoclonal antibody (mAb)	Infectious disease (Flu) and related syndrome					
				syndrome evaluation.		evaluation.					

For inquiry please click here to contact us or send email to support@genemedi.net

Human immunodeficiency virus 1 (HIV-1)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-IVD- P003-Tg001	Human immunodeficiency virus 1 (HIV-1)	GP41 Protein	Acquired	Recombinant Human	Human immunodeficiency virus 1 (GP41 Protein) antibodies binding, Immunogen in Sandwich Elisa, lateral- flow tests, and other immunoassays as control material in GP41 Protein level test of Infectious disease (Acquired immunodeficiency syndrome(AIDS)) and related syndrome evaluation.	Anti-Human immunodeficiency virus 1 (HIV-1) GP41 Protein mouse	Human immunodeficiency virus 1 (GP41 Protein) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Human immunodeficiency virus 1 (GP41 Protein) antibodies in GP41 Protein level test of Infectious disease (Acquired immunodeficiency syndrome(AIDS)) and related syndrome evaluation.	=

Human in	Human immunodeficiency virus 2 (HIV-2)							
Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
							Human immunodeficiency virus 2 (GP36	
					Human immunodeficiency virus 2		Protein) antigen binding, ELISA validated as	
					(GP36 Protein) antibodies binding,	GMP-IVD-P004-Tg001-Ab01;	capture antibody and detection antibody. Pair	
	Liberto and			GMP-IVD-P004-Tg001-Ag01:	Immunogen in Sandwich Elisa, lateral-	GMP-IVD-P004-Tg001-Ab02:		
GMP-IVD-	Human		Acquired	Recombinant Human	flow tests, and other immunoassays as	Anti-Human	recommendation with other Human	
P004-Tg001	immunodeficiency	GP36 Protein	immunodeficiency	immunodeficiency virus 2	control material in GP36 Protein level	immunodeficiency virus 2	immunodeficiency virus 2 (GP36 Protein)	=
	virus 2 (HIV-2)		syndrome(AIDS)				antibodies in GP36 Protein level test of	
				(HIV-2) GP36 Protein Protein	test of Infectious disease (Acquired	(HIV-2) GP36 Protein mouse	Infectious disease (Acquired immunodeficiency	,
					immunodeficiency syndrome(AIDS))	monoclonal antibody (mAb)	syndrome(AIDS)) and related syndrome	
					and related syndrome evaluation.		, , ,,	
							evaluation.	

immunodeficiency virus 1/2 (HIV1/2)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
				GMP-IVD-P005-Tg001-Ag01:	immunodeficiency virus 1/2 (HIV p24 antigen) antibodies binding,	GMP-IVD-P005-Tg001-Ab01; GMP-IVD-P005-Tg001-Ab02:	antigen binding, ELISA validated as capture	
GMP-IVD-	immunodeficiency	HIV p24		Recombinant	Immunogen in Sandwich Elisa, lateral-		antibody and detection antibody. Pair	
P005-Tg001	virus 1/2 (HIV1/2)	antigen	AIDS	immunodeficiency virus 1/2	flow tests, and other immunoassays as		recommendation with other immunodeficiency	₩
				(HIV1/2) HIV p24 antigen	control material in HIV p24 antigen	mouse monoclonal antibody	virus 1/2 (HIV p24 antigen) antibodies in HIV	
				Protein	level test of Infectious disease (AIDS)	(mAb)	p24 antigen level test of Infectious disease	
					and related syndrome evaluation.		(AIDS) and related syndrome evaluation.	

For inquiry please click here to contact us or send email to support@genemedi.net

immunodeficiency virus-O antigen (HIV-O)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
					immunodeficiency virus-O antigen (O-	GMP-IVD-P006-Tg001-Ab01;	immunodeficiency virus-O antigen (O-antigen)	
				GMP-IVD-P006-Tg001-Ag01:	antigen) antibodies binding,	GMP-IVD-P006-Tg001-Ab02:	antigen binding, ELISA validated as capture	
GMP-IVD-	immunodeficiency			Recombinant	Immunogen in Sandwich Elisa, lateral-	Anti-immunodeficiency virus-O	antibody and detection antibody. Pair	
P006-Tg001	virus-O antigen	O-antigen	AIDS	immunodeficiency virus-O	flow tests, and other immunoassays as		recommendation with other immunodeficiency	₩
	(HIV-O)			antigen (HIV-O) O-antigen	control material in O-antigen level test	mouse monoclonal antibody	virus-O antigen (O-antigen) antibodies in O-	
				Protein	of Infectious disease (AIDS) and	(mAb)	antigen level test of Infectious disease (AIDS)	
					related syndrome evaluation.		and related syndrome evaluation.	

For inquiry please click here to contact us or send email to support@genemedi.net

hepatitis C virus (HCV)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Orde	
GMP-IVD- hepatitis C P007-Tg001 virus (HCV)			Hepatitis C		HCV core antigen (Recombinant HCV NS3-NS4-NS5 fusion Protein (His Tag))		HCV core antigen (Recombinant HCV NS3- NS4-NS5 fusion Protein (His Tag)) antigen binding, ELISA validated as capture antibody		
	hepatitis C	HCV NS3- NS4-NS5		Recombinant hepat Hepatitis C virus (HCV) Recombinat NS3-NS4-NS5 fusion	GMP-IVD-P007-Tg001-Ag01: Recombinant hepatitis C virus (HCV) Recombinant HCV	antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material	Anti-hepatitis C virus (HCV) with other HCV c	and detection antibody. Pair recommendation with other HCV core antigen (Recombinant HCV	
	fusion Protein (His Tag)	riopanio c				NS3-NS4-NS5 fusion Protein (His Tag) Protein	in Recombinant HCV NS3-NS4-NS5 fusion Protein (His Tag) level test of	NS5 fusion Protein (His Tag) mouse monoclonal antibody	NS3-NS4-NS5 fusion Protein (His Tag)) antibodies in Recombinant HCV NS3-NS4-NS5
		, 0/			Infectious disease (Hepatitis C) and related syndrome evaluation.	(mAb)	fusion Protein (His Tag) level test of Infectious disease (Hepatitis C) and related syndrome evaluation.		

For inquiry please click here to contact us or send email to support@genemedi.net

Treponema Pallidum (TP)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
							Treponema Pallidum (Recombinant TP P15-	
					Treponema Pallidum (Recombinant TP		D17 D47 fusion Protein (His Tog.)\ antigen	
					P15-P17-P47 fusion Protein (His Tag))	GMP-IVD-P008-Tg001-Ab01;	P17-P47 fusion Protein (His Tag)) antigen	
		Recombinant		CMD IV/D D000 Ta004 Aa04.	antihadiaa hinding Immunagan in	CMD IVD D000 T~004 Ab02:	binding, ELISA validated as capture antibody	
		Recombinant		GMP-IVD-P008-Tg001-Ag01:	antibodies binding, Immunogen in	GMP-IVD-P008-Tg001-Ab02:	and detection antibody. Pair recommendation	
CMD IV/D	T	TP P15-P17-		Recombinant Treponema	Sandwich Elisa, lateral-flow tests, and	Anti-Treponema Pallidum (TP)		
GMP-IVD-	Treponema	P47 fusion	syphilis	Pallidum (TP) Recombinant	other immunoassays as control material	Recombinant TP P15-P17-	with other Treponema Pallidum (Recombinant	_
P008-Tg001	Pallidum (TP)		- 71		·		TP P15-P17-P47 fusion Protein (His Tag))	"
		Protein (His		TP P15-P17-P47 fusion	in Recombinant TP P15-P17-P47 fusion	P47 fusion Protein (His Tag)	antibodies in Recombinant TP P15-P17-P47	
		Tag)		Protein (His Tag) Protein	Protein (His Tag) level test of Infectious	mouse monoclonal antibody		
					disease (syphilis) and related syndrome	(mAb)	fusion Protein (His Tag) level test of Infectious	
					, , , ,	(117 10)	disease (syphilis) and related syndrome	
					evaluation.		evaluation.	

Toxoplasma gondii (T. gondii)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-IVD- P009-Tg001	Toxoplasma gondii (T. gondii)	P30	Toxoplasmosis	GMP-IVD-P009-Tg001-Ag01: Recombinant Toxoplasma gondii (T. gondii) P30 Protein	toxoplasma gondii (P30) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in P30 level test of Infectious disease (Toxoplasmosis) and related syndrome	GMP-IVD-P009-Tg001-Ab02: Anti-Toxoplasma gondii (T. gondii) P30 mouse	toxoplasma gondii (P30) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other toxoplasma gondii (P30) antibodies in P30 level test of Infectious disease (Toxoplasmosis) and related syndrome evaluation.	.

For inquiry please click here to contact us or send email to support@genemedi.net

rubella virus

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-IVD- P010-Tg001	rubella virus	CAPSID (C)	Rubella or German measles or three- day measlesis	GMP-IVD-P010-Tg001-Ag01: Recombinant rubella virus CAPSID (C) Protein	rubella virus (CAPSID (C)) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in CAPSID (C) level test of Infectious disease (Rubella or German measles or three-day measlesis) and related syndrome evaluation.	GMP-IVD-P010-Tg001-Ab01; GMP-IVD-P010-Tg001-Ab02: Anti-rubella virus CAPSID (C) mouse monoclonal antibody (mAb)	rubella virus (CAPSID (C)) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other rubella virus (CAPSID (C)) antibodies in CAPSID (C) level test of Infectious disease (Rubella or German measles or three-day measlesis) and related syndrome evaluation.	₩
GMP-IVD- P010-Tg002	rubella virus	Nucleoprotein	Rubella	GMP-IVD-P010-Tg002-Ag01: Recombinant rubella virus Nucleoprotein Protein	rubella virus (Nucleoprotein) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Nucleoprotein level test of Infectious disease (Rubella) and related syndrome evaluation.		rubella virus (Nucleoprotein) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other rubella virus (Nucleoprotein) antibodies in Nucleoprotein level test of Infectious disease (Rubella) and related syndrome evaluation.	=

For inquiry please click here to contact us or send email to support@genemedi.net

Cytomegalovirus (CMV)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-IVD- P011-Tg001	Cytomegalovirus (CMV)	pp65	chickenpox, herpes simplex and mononucleosis	GMP-IVD-P011-Tg001-Ag01: Recombinant Cytomegalovirus (CMV) pp65 Protein	lateral-flow tests, and other immunoassays as control material in	GMP-IVD-P011-Tg001-Ab01; GMP-IVD-P011-Tg001-Ab02: Anti-Cytomegalovirus (CMV) pp65 mouse monoclonal antibody (mAb)	Cytomegalovirus (pp65) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Cytomegalovirus (pp65) antibodies in pp65 leve test of Infectious disease (chickenpox, herpes simplex and mononucleosis) and related syndrome evaluation.	

For inquiry please click here to contact us or send email to support@genemedi.net

herpes simplex virus (HSV)

Target Disease Cat No.of Antigen	Cat No. Pathogen	Patho	No. Pathogen Target Disease Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
				herpes simplex virus antibodies			
HSV-1 and HSV-2, can			HSV-1 and HSV-2 can	binding, Immunogen in Sandwich		herpes simplex virus antigen binding, ELISA	
cause oral or genital				Elisa, lateral-flow tests, and other		validated as capture antibody and detection	
infection. Most often,				immunoassays as control material in		antibody. Pair recommendation with other	
HSV-1				herpes simplex virus level test of		herpes simplex virus antibodies in herpes	
causes gingivostomatitis,				Infectious disease (HSV-1 and HSV-2,	GMP-IVD-P012-Tg001-Ab01;		
	herpes	herp	herpes GMP-IVD-P012-Tg001-Ag01:	can cause oral or genital infection.	GMP-IVD-P012-Tg001-Ab02:		
pprotein G Recombinant herpes simplex herpes keratitis. HSV-2	012-Tg001			Most often, HSV-1	Anti-herpes simplex virus	infection. Most often, HSV-1	₩
usually causes genital virus (HSV) Protein	(HSV)	(HS		causes gingivostomatitis, herpes	(HSV) mouse monoclonal	causes gingivostomatitis, herpes labialis, and	
lesions. Generally,			lesions. Generally,	labialis, and herpes keratitis. HSV-2	antibody (mAb)	herpes keratitis. HSV-2 usually causes genital	
recurrent eruptions are			·			lesions. Generally, recurrent eruptions are less	
less severe and occur			less severe and occur			severe and occur less frequently over time.)	
less frequently over time.				, ,		and related syndrome evaluation.	
				,			
less severe and occur			less severe and occur	usually causes genital lesions. Generally, recurrent eruptions are less severe and occur less frequently over time.) and related syndrome evaluation.		severe and occur less frequently o	ver time.)

Herpes simplex virus 1 (HSV-1)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-IVD- P013-Tg001	Herpes simplex virus 1 (HSV-1)	glycoprotein G (gG-1)	oral herpes	GMP-IVD-P013-Tg001-Ag01: Recombinant Herpes simplex virus 1 (HSV-1) glycoprotein G (gG-1) Protein	Herpes simplex virus 1 (glycoprotein G (gG-1)) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in glycoprotein G (gG-1) level test of Infectious disease (oral herpes) and related syndrome evaluation.	GMP-IVD-P013-Tg001-Ab01; GMP-IVD-P013-Tg001-Ab02: Anti-Herpes simplex virus 1 (HSV-1) glycoprotein G (gG-1) mouse monoclonal antibody (mAb)	Herpes simplex virus 1 (glycoprotein G (gG-1)) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Herpes simplex virus 1 (glycoprotein G (gG-1)) antibodies in glycoprotein G (gG-1) level test of Infectious disease (oral herpes) and related syndrome evaluation.	₩

For inquiry please click here to contact us or send email to support@genemedi.net

Herpes simplex virus 2 (HSV-2)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
					Herpes simplex virus 2 (glycoprotein G		Herpes simplex virus 2 (glycoprotein G (gG-2))	,
					(gG-2)) antibodies binding, Immunogen	GMP-IVD-P014-Tg001-Ab01;	antigen binding, ELISA validated as capture	
	Hornoo			GMP-IVD-P014-Tg001-Ag01:	in Sandwich Elisa, lateral-flow tests,	GMP-IVD-P014-Tg001-Ab02:	antibody and detection antibody. Pair	
GMP-IVD-	simplex virus 2	glycoprotein G (gG-2)		Recombinant Herpes simplex	and other immunoassays as control	Anti-Herpes simplex virus 2	recommendation with other Herpes simplex	
P014-Tg001			genital herpes (gG-2)	virus 2 (HSV-2) glycoprotein G	material in glycoprotein G (gG-2) level	(HSV-2) glycoprotein G (gG-2)	virus 2 (glycoprotein G (gG-2)) antibodies in	=
				(gG-2) Protein	test of Infectious disease (genital	mouse monoclonal antibody	glycoprotein G (gG-2) level test of Infectious	
					herpes) and related syndrome	(mAb)	disease (genital herpes) and related syndrome	
					evaluation.		evaluation.	

For inquiry please click here to contact us or send email to support@genemedi.net

Bacillus anthracis (B. anthracis)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Orde
					anthrax bacillus (protective antigen		anthrax bacillus (protective antigen (PA)) antigen	n
					(PA)) antibodies binding, Immunogen in		binding, ELISA validated as capture antibody	
	Bacillus			GMP-IVD-P015-Tg001-Ag01:	Sandwich Elisa, lateral-flow tests, and	GMP-IVD-P015-Tg001-Ab02:	and detection antibody. Pair recommendation	
GMP-IVD-	anthracis (B.	protective	Anthrax		other immunoassays as control material	Anti-Bacillus anthracis (B.	with other anthrax bacillus (protective antigen	=
P015-Tg001	anthracis)	antigen (PA)		anthracis (B. anthracis)	in protective antigen (PA) level test of	anthracis) protective antigen	(PA)) antibodies in protective antigen (PA) level	i
				protective antigen (PA) Protein	Infectious disease (Anthrax) and related	(PA) mouse monoclonal	test of Infectious disease (Anthrax) and related	
					syndrome evaluation.	antibody (mAb)	syndrome evaluation.	

For inquiry please click here to contact us or send email to support@genemedi.net

Ebola virus (EV)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order

ebola virus (nucleoprotein (NP)) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and Other immunoassays as control material in nucleoprotein (NP) ebola virus (EV) P016-Tg001 (EV) (NP) Disease ebola virus (nucleoprotein (NP)) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in nucleoprotein (NP) level test of nucleoprotein (NP) mouse in nucleoprotein (NP) mouse in nucleoprotein (NP) mouse in nucleoprotein (NP) mouse in nucleoprotein (NP) mouse	Pathogen Target Disease	. Pathogen	Cat No.
Infectious disease (Ebola Virus Disease) and related syndrome evaluation. monoclonal antibody (mAb) disease (Ebola Virus Disease) and syndrome evaluation.	ebola virus nucleoprotein Ebola Virus	O- ebola virus	GMP-IVD-

Vaccinia virus (cowpox virus)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
					Vaccinia virus (cowpox virus) A27L		Vaccinia virus (cowpox virus) A27L antigen	
					antibodies binding, Immunogen in	GMP-IVD-P017-Tg001-Ab01;	binding, ELISA validated as capture antibody	
GMP-IVD-	Vaccinia virus			GMP-IVD-P017-Tg001-Ag01:	Sandwich Elisa, lateral-flow tests, and	GMP-IVD-P017-Tg001-Ab02:	and detection antibody. Pair recommendation	
P017-Tg001	(cowpox virus)	A27L	Cowpox	Recombinant Vaccinia virus	other immunoassays as control material	Anti-Vaccinia virus (cowpox	with other Vaccinia virus (cowpox virus) A27L	=
1017-19001	(cowpox virus)			(cowpox virus) A27L Protein	in A27L level test of Infectious disease	virus) A27L mouse	antibodies in A27L level test of Infectious	
					(Cowpox) and related syndrome	monoclonal antibody (mAb)	disease (Cowpox) and related syndrome	
					evaluation.		evaluation.	
GMP-IVD- P017-Tg002	Vaccinia virus (cowpox virus)	h3I	Cowpox	GMP-IVD-P017-Tg002-Ag01: Recombinant Vaccinia virus (cowpox virus) h3l Protein	Vaccinia virus (cowpox virus) h3l antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in h3l level test of Infectious disease (Cowpox) and related syndrome evaluation.	GMP-IVD-P017-Tg002-Ab01; GMP-IVD-P017-Tg002-Ab02: Anti-Vaccinia virus (cowpox virus) h3l mouse monoclonal antibody (mAb)	Vaccinia virus (cowpox virus) h3l antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Vaccinia virus (cowpox virus) h3l antibodies in h3l level test of Infectious disease (Cowpox) and related syndrome evaluation.	=
GMP-IVD- P017-Tg003	Vaccinia virus (cowpox virus)	b5r	Cowpox	GMP-IVD-P017-Tg003-Ag01: Recombinant Vaccinia virus (cowpox virus) b5r Protein	Vaccinia virus (cowpox virus) b5r antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in b5r level test of Infectious disease (Cowpox) and related syndrome evaluation.	GMP-IVD-P017-Tg003-Ab01; GMP-IVD-P017-Tg003-Ab02: Anti-Vaccinia virus (cowpox virus) b5r mouse monoclonal antibody (mAb)	Vaccinia virus (cowpox virus) b5r antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Vaccinia virus (cowpox virus) b5r antibodies in b5r level test of Infectious disease (Cowpox) and related syndrome evaluation.	₩

For inquiry please click here to contact us or send email to support@genemedi.net

West Nile virus (WNV)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Orde
					West Nile virus (envelope (E))		West Nile virus (envelope (E)) antigen binding,	
					antibodies binding, Immunogen in	GMP-IVD-P018-Tg001-Ab01;	ELISA validated as capture antibody and	
CMP IVP	West Nile virus			GMP-IVD-P018-Tg001-Ag01:	Sandwich Elisa, lateral-flow tests, and	GMP-IVD-P018-Tg001-Ab02:	detection antibody. Pair recommendation with	
GMP-IVD- P018-Tg001		envelope (E)	West Nile fever	Recombinant West Nile virus	other immunoassays as control material	Anti-West Nile virus (WNV)	other West Nile virus (envelope (E)) antibodies	=
P016-19001	(WNV)			(WNV) envelope (E) Protein	in envelope (E) level test of Infectious	envelope (E) mouse	in envelope (E) level test of Infectious disease	
					disease (West Nile fever) and related	monoclonal antibody (mAb)	(West Nile fever) and related syndrome	
					syndrome evaluation.		evaluation.	

For inquiry please click here to contact us or send email to support@genemedi.net

Adenovirus

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-IVD- P019-Tg001	adenovirus	Hexon	cold-like symptoms, fever, sore throat, bronchitis, pneumonia, diarrhea, and pink eye (conjunctivitis)	GMP-IVD-P019-Tg001-Ag01:	adenovirus (Hexon) antibodies binding, Immunogen in Sandwich Elisa, lateral- flow tests, and other immunoassays as control material in Hexon level test of Infectious disease (cold-like symptoms, fever, sore throat, bronchitis, pneumonia, diarrhea, and pink eye (conjunctivitis)) and related syndrome evaluation.	GMP-IVD-P019-Tg001-Ab01; GMP-IVD-P019-Tg001-Ab02: Anti-adenovirus (Hexon) mouse monoclonal antibody	adenovirus Hexon antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other (Hexon) antibodies in Hexon level test of Infectious disease (cold-like symptoms, fever, sore throat, bronchitis, pneumonia, diarrhea, and pink eye (conjunctivitis)) and related syndrome evaluation.	d

Plasmodium [Plasmodium falciparum] [Plasmodium knowlesi] [Plasmodium malariae] [Plasmodium ovale] [Plasmodium vivax]

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
					Plasmodium (Circumsporozoite		Plasmodium malaria (Circumsporozoite	
	Plasmodium				Protein (CSP)) antibodies binding,	GMP-IVD-P020-Tg001-Ab01;	Protein (CSP)) antigen binding, ELISA	
	[Plasmodium falciparum]	merozoite		GMP-IVD-P020-Tg001-Ag01:	Immunogen in Sandwich Elisa,	GMP-IVD-P020-Tg001-Ab02:	validated as capture antibody and detection	
GMP-IVD-	[Plasmodium knowlesi]	surface protein	malaria	Recombinant Plasmodium	lateral-flow tests, and other	Anti-Plasmodium merozoite	antibody. Pair recommendation with other	-
P020-Tg001	[Plasmodium malariae]	(MSP)	maiana	merozoite surface protein	immunoassays as control material in		Plasmodium (Circumsporozoite Protein	7
	[Plasmodium ovale]	()		(MSP) Protein	CSP level test of Infectious	monoclonal antibody (mAb)	(CSP)) antibodies in CSP level test of	
	[Plasmodium vivax]				disease(malaria) and related		Infectious disease (malaria) and related	
					syndrome evaluation.		syndrome evaluation.	
					malaria (Circumsporozoite Protein		malaria (Circumsporozoite Protein (CSP))	
	Plasmodium				(CSP)) antibodies binding,	GMP-IVD-P020-Tg002-Ab01;	antigen binding, ELISA validated as capture	
	[Plasmodium falciparum]			GMP-IVD-P020-Tg002-Ag01:	Immunogen in Sandwich Elisa,	GMP-IVD-P020-Tg002-Ab02:	antibody and detection antibody. Pair	
GMP-IVD-	[Plasmodium knowlesi]	Circumsporozoite	malaria	Recombinant Plasmodium	lateral-flow tests, and other	Anti-Plasmodium	recommendation with other malaria	=
P020-Tg002	[Plasmodium malariae]	Protein (CSP)		Circumsporozoite Protein	immunoassays as control material in	Circumsporozoite Protein	(Circumsporozoite Protein (CSP)) antibodies	
	[Plasmodium ovale]			(CSP) Protein	MSP level test of Infectious disease	(CSP) mouse monoclonal	in MSP level test of Infectious disease	
	[Plasmodium vivax]				(malaria) and related syndrome	antibody (mAb)	(malaria) and related syndrome evaluation.	
					evaluation.		indiana, and rolated syndrome sydication.	

For inquiry please click here to contact us or send email to support@genemedi.net

Astrovirus

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
					Astrovirus (capsid proteins) antibodies		Astrovirus (capsid proteins) antigen binding,	
					binding, Immunogen in Sandwich Elisa,	GMP-IVD-P021-Tg001-Ab01;	ELISA validated as capture antibody and	
GMP-IVD-				GMP-IVD-P021-Tg001-Ag01:	lateral-flow tests, and other	GMP-IVD-P021-Tg001-Ab02:	detection antibody. Pair recommendation with	
	Astrovirus	capsid proteins	gastroenteritis	Recombinant Astrovirus	immunoassays as control material in	Anti-Astrovirus capsid proteins	other Astrovirus (capsid proteins) antibodies in	=
P021-Tg001				capsid proteins Protein	capsid proteins level test of Infectious	mouse monoclonal antibody	capsid proteins level test of Infectious disease	
					disease (gastroenteritis) and related	(mAb)	(gastroenteritis) and related syndrome	
					syndrome evaluation.		evaluation.	

For inquiry please click here to contact us or send email to support@genemedi.net

Norovirus (NV)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-IVD- P022-Tg001	Norovirus (NV)	VP1	vomiting and diarrhea	GMP-IVD-P022-Tg001-Ag01: Recombinant Norovirus (NV) VP1 Protein	Norovirus (VP1) antibodies binding, Immunogen in Sandwich Elisa, lateral- flow tests, and other immunoassays as control material in VP1 level test of Infectious disease (vomiting and diarrhea) and related syndrome evaluation.		Norovirus (VP1) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Norovirus (VP1) antibodies in VP1 level test of Infectious disease (vomiting and diarrhea) and related syndrome evaluation.	

For inquiry please click here to contact us or send email to support@genemedi.net

Campylobacter jejuni (C. jejuni)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
					Campylobacter jejuni (Outer Membrane		Campylobacter jejuni (Outer Membrane Protein	1
					Protein (OMP)) antibodies binding,	GMP-IVD-P023-Tg001-Ab01;	(OMP)) antigen binding, ELISA validated as	
	Campylobacter	Outer		GMP-IVD-P023-Tg001-Ag01:	Immunogen in Sandwich Elisa, lateral-	GMP-IVD-P023-Tg001-Ab02:	capture antibody and detection antibody. Pair	
GMP-IVD-	jejuni (C.	Membrane	gastroenteritis	Recombinant Campylobacter	flow tests, and other immunoassays as	Anti-Campylobacter jejuni (C.	recommendation with other Campylobacter	
P023-Tg001	jejuni)	Protein (OMP)	g	jejuni (C. jejuni) Outer	control material in Outer Membrane	jejuni) Outer Membrane	jejuni (Outer Membrane Protein (OMP))	
	J - J ,	,		Membrane Protein (OMP)	Protein (OMP) level test of Infectious	Protein (OMP) mouse	antibodies in Outer Membrane Protein (OMP)	
					disease (gastroenteritis) and related	monoclonal antibody (mAb)	level test of Infectious disease (gastroenteritis)	
					syndrome evaluation.		and related syndrome evaluation.	

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
					Campylobacter jejuni (Flagellar L-ring		Campylobacter jejuni (Flagellar L-ring protein	
					protein (FLGH)) antibodies binding,	GMP-IVD-P023-Tg002-Ab01;	(FLGH)) antigen binding, ELISA validated as	
	Camanidah aatam			GMP-IVD-P023-Tg002-Ag01:	Immunogen in Sandwich Elisa, lateral-	GMP-IVD-P023-Tg002-Ab02:	capture antibody and detection antibody. Pair	
GMP-IVD-		Flagellar L-ring		Recombinant Campylobacter	flow tests, and other immunoassays as	Anti-Campylobacter jejuni (C.	recommendation with other Campylobacter	
P023-Tg002		protein (FLGH)	gastroenteritis	jejuni (C. jejuni) Flagellar L-	control material in Flagellar L-ring	jejuni) Flagellar L-ring protein	jejuni (Flagellar L-ring protein (FLGH))	=
	jejuni)			ring protein (FLGH) Protein	protein (FLGH) level test of Infectious	(FLGH) mouse monoclonal	antibodies in Flagellar L-ring protein (FLGH)	
					disease (gastroenteritis) and related	antibody (mAb)	level test of Infectious disease (gastroenteritis)	
					syndrome evaluation.		and related syndrome evaluation.	

Listeria monocytogenes (L. monocytogenes)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
P024-Tg001	Listeria monocytogenes (L. monocytogenes)	Listeriolysin O (LLO)	Listeriosis	GMP-IVD-P024-Tg001-Ag01: Recombinant Listeria monocytogenes (L. monocytogenes) Listeriolysin O (LLO) Protein	Listeria monocytogenes (Listeriolysin O (LLO)) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Listeriolysin O (LLO) level test of Infectious disease (Listeriosis) and related syndrome evaluation.	GMP-IVD-P024-Tg001-Ab01; GMP-IVD-P024-Tg001-Ab02: Anti-Listeria monocytogenes (L. monocytogenes) Listeriolysin O (LLO) mouse monoclonal antibody (mAb)	Listeria monocytogenes (Listeriolysin O (LLO)) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Listeria monocytogenes (Listeriolysin O (LLO)) antibodies in Listeriolysin O (LLO) level test of Infectious disease (Listeriosis) and related syndrome evaluation.	₩

For inquiry please click here to contact us or send email to support@genemedi.net

Rotavirus

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-IVD- P025-Tg001	rotavirus	VP6	watery diarrhea and vomiting	GMP-IVD-P025-Tg001-Ag01: Recombinant rotavirus VP6 Protein	rotavirus (VP6) antibodies binding, Immunogen in Sandwich Elisa, lateral- flow tests, and other immunoassays as control material in VP6 level test of Infectious disease (watery diarrhea and vomiting) and related syndrome evaluation.	GMP-IVD-P025-Tg001-Ab01; GMP-IVD-P025-Tg001-Ab02: Anti-rotavirus VP6 mouse	rotavirus (VP6) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other rotavirus (VP6) antibodies in VP6 level test of Infectious disease (watery diarrhea and vomiting) and related syndrome evaluation.	

For inquiry please click here to contact us or send email to support@genemedi.net

Salmonella typhi

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Orde
					salmonella (outer membrane channel		salmonella (outer membrane channel protein	
					protein (Tolc) OMP 50 (Salmonella	GMP-IVD-P026-Tg001-Ab01;	(Tolc) OMP 50 (Salmonella typhi)) antigen	
		outer		GMP-IVD-P026-Tg001-Ag01:	typhi)) antibodies binding, Immunogen	GMP-IVD-P026-Tg001-Ab02:	binding, ELISA validated as capture antibody	
		membrane		Recombinant Salmonella typhi	in Sandwich Elisa, lateral-flow tests,	Anti-Salmonella typhi outer	and detection antibody. Pair recommendation	
GMP-IVD-	Salmonella	channel protein	Salmonellosis	outer membrane channel	and other immunoassays as control	membrane channel protein	with other salmonella (outer membrane channel	4
P026-Tg001	typhi	(Tolc) OMP 50		protein (Tolc) OMP 50	material in outer membrane channel	(Tolc) OMP 50 (Salmonella	protein (Tolc) OMP 50 (Salmonella typhi))	"
		(Salmonella		(Salmonella typhi) Protein	protein (Tolc) OMP 50 (Salmonella	typhi) mouse monoclonal	antibodies in outer membrane channel protein	
		typhi)		, , ,	typhi) level test of Infectious disease	antibody (mAb)	(Tolc) OMP 50 (Salmonella typhi) level test of	
					(Salmonellosis) and related syndrome		Infectious disease (Salmonellosis) and related	
					evaluation.		syndrome evaluation.	

For inquiry please click here to contact us or send email to support@genemedi.net

Candida albicans (C. albicans)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-IVD-P027-Tg001	Candida albicans (C.	enolase (Candida albicans)	Candidiasis	GMP-IVD-P027-Tg001-Ag01:	candida (enolase (Candida albicans)) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material	GMP-IVD-P027-Tg001-Ab01; GMP-IVD-P027-Tg001-Ab02: Anti-Candida albicans (C. albicans) enolase (Candida albicans) mouse monoclonal	candida (enolase (Candida albicans)) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other candida (enolase (Candida albicans)) antibodies in enolase (Candida albicans) level test of Infectious disease (Candidiasis) and))) 💆
					related syndrome evaluation.	antibody (mAb)	related syndrome evaluation.	

Human papilloma virus (HPV)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
					papilloma virus (HPV 16 L1 capsid		papilloma virus (HPV 16 L1 capsid protein)	
					protein) antibodies binding, Immunogen	GMP-IVD-P028-Tg001-Ab01;	antigen binding, ELISA validated as capture	
	Lluman			GMP-IVD-P028-Tg001-Ag01:	in Sandwich Elisa, lateral-flow tests,	GMP-IVD-P028-Tg001-Ab02:	antibody and detection antibody. Pair	
GMP-IVD-	Human	HPV 16 L1	cervical and	Recombinant Human	and other immunoassays as control	Anti-Human papilloma virus	recommendation with other papilloma virus	
P028-Tg001		capsid protein	other cancers	papilloma virus (HPV) HPV 16	material in HPV 16 L1 capsid protein	(HPV) HPV 16 L1 capsid	(HPV 16 L1 capsid protein) antibodies in HPV	=
	(HPV)			L1 capsid protein Protein	level test of Infectious disease (cervical	protein mouse monoclonal	16 L1 capsid protein level test of Infectious	
					and other cancers) and related	antibody (mAb)	disease (cervical and other cancers) and related	Ł
					syndrome evaluation.		syndrome evaluation.	

For inquiry please click here to contact us or send email to support@genemedi.net

Hepatitis b virus (HBV)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-IVD- P029-Tg001	Hepatitis b virus (HBV)	HBsAg (hepatitis B surface antigen)	Hepatitis B	GMP-IVD-P029-Tg001-Ag01: Recombinant Hepatitis b virus (HBV) HBsAg Protein	Hepatitis B s antigen (HBsAg) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in HBsAg level test of Infectious disease (Hepatitis B) and related syndrome evaluation.	GMP-IVD-P029-Tg001-Ab01; GMP-IVD-P029-Tg001-Ab02: Anti-Hepatitis B virus (HBV) HBsAg mouse monoclonal antibody (mAb)	Hepatitis B s antigen (HBsAg) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Hepatitis B s antigen (HBsAg) antibodies in HBsAg level test of Infectious disease (Hepatitis B) and related syndrome evaluation.	=
GMP-IVD- P029-Tg002	Hepatitis B virus (HBV)	HBeAg (hepatitis B e-antigen)	Hepatitis B	GMP-IVD-P029-Tg002-Ag01: Recombinant Hepatitis B virus (HBV) HBeAg Protein	Hepatitis B e antigen (HBeAg) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in HBeAg level test of Infectious disease (Hepatitis B) and related syndrome evaluation.	GMP-IVD-P029-Tg002-Ab01; GMP-IVD-P029-Tg002-Ab02: Anti-Hepatitis B virus (HBV) HBeAg mouse monoclonal antibody (mAb)	Hepatitis B e antigen (HBeAg) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other hepatitis B e antigen (HBeAg) antibodies in HBeAg level test of Infectious disease (Hepatitis B) and related syndrome evaluation.	₩.
GMP-IVD- P029-Tg003	Hepatitis B virus (HBV)	HBcAg (hepatitis B Core antigen)	Hepatitis B	GMP-IVD-P029-Tg003-Ag01: Recombinant Hepatitis B virus (HBV) HBcAg Protein	Hepatitis B core antigen (HBcAg) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in HBcAg level test of Infectious disease (Hepatitis B) and related syndrome evaluation.	GMP-IVD-P029-Tg003-Ab01; GMP-IVD-P029-Tg003-Ab02: Anti-Hepatitis B virus (HBV) HBcAg mouse monoclonal antibody (mAb)	Hepatitis B core antigen (HBcAg) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other hepatitis B core antigen (HBcAg) antibodies in HBcAg level test of Infectious disease (Hepatitis B) and related syndrome evaluation.	₩

For inquiry please click here to contact us or send email to support@genemedi.net

Hepatitis B virus-PreS1 (HBV-PreS1)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-IVD- P030-Tg001	Hepatitis B virus-PreS1 (HBV-PreS1)	PreS1	Hepatitis B	GMP-IVD-P030-Tg001-Ag01: Recombinant Hepatitis B virus- PreS1 (HBV-PreS1) PreS1 Protein	Sandwich Elisa, lateral-flow tests, and	Anti-Hepatitis B virus-PreS1	ELISA validated as capture antibody and	

Food source pathogenic bacteria resistant

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
					Food source pathogenic bacteria		Food source pathogenic bacteria resistant	
					resistant antibodies binding,		antigen binding, ELISA validated as capture	
				GMP-IVD-P031-Tg001-Ag01:	Immunogen in Sandwich Elisa, lateral-	GMP-IVD-P031-Tg001-Ab01;	antibody and detection antibody. Pair	
GMP-IVD-			Food source	Recombinant Food source	flow tests, and other immunoassays as	GMP-IVD-P031-Tg001-Ab02:	recommendation with other Food source	
P031-Tg001	NA	NA	pathogenic	pathogenic bacteria resistant	control material in Food source	Anti-Food source pathogenic	pathogenic bacteria resistant antibodies in Food	d 🛒
F031-19001			bacteria resistant		pathogenic bacteria resistant level test	bacteria resistant mouse	source pathogenic bacteria resistant level test o	of
				FloteIII	of Infectious disease (Food source	monoclonal antibody (mAb)	Infectious disease (Food source pathogenic	
					pathogenic bacteria resistant) and		bacteria resistant) and related syndrome	
					related syndrome evaluation.		evaluation.	

For inquiry please click here to contact us or send email to support@genemedi.net

Rift Valley Fever (RVF)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
					Rift Valley Fever (nucleoprotein (NP))		Rift Valley Fever (nucleoprotein (NP)) antigen	
				OMD IV/D D000 T-004 A-04-	antibodies binding, Immunogen in	GMP-IVD-P032-Tg001-Ab01;	binding, ELISA validated as capture antibody	
OMP IVE	D.0.77.11			GMP-IVD-P032-Tg001-Ag01:	Sandwich Elisa, lateral-flow tests,and	GMP-IVD-P032-Tg001-Ab02:	and detection antibody. Pair recommendation	
GMP-IVD-	Rift Valley	nucleoprotein	Rift Valley Fever		other immunoassays as control material	Anti-Rift Valley Fever (RVF)	with other Rift Valley Fever (nucleoprotein (NP))	·) 🛒
P032-Tg001	Fever (RVF)	(NP)		(RVF) nucleoprotein (NP)	in nucleoprotein (NP) level test of	nucleoprotein (NP) mouse	antibodies in nucleoprotein (NP) level test of	
				Protein	Infectious disease(Rift Valley Fever)	monoclonal antibody (mAb)	Infectious disease (Rift Valley Fever) and related	d
					and related syndrome evaluation.		syndrome evaluation.	

For inquiry please click here to contact us or send email to support@genemedi.net

Epstein-Barr virus (EBV)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
					Epstein-Barr virus (Nuclear Antigen		Epstein-Barr virus (Nuclear Antigen (EBNA1))	
					(EBNA1)) antibodies binding,	GMP-IVD-P033-Tg001-Ab01;	antigen binding, ELISA validated as capture	
		Nuclear		GMP-IVD-P033-Tg001-Ag01:	Immunogen in Sandwich Elisa, lateral-	GMP-IVD-P033-Tg001-Ab02:	antibody and detection antibody. Pair	
GMP-IVD-	Epstein-Barr	Antigen	infectious	Recombinant Epstein-Barr	flow tests,and other immunoassays as	Anti-Epstein-Barr virus (EBV)	recommendation with other Epstein-Barr virus	
P033-Tg001	virus (EBV)	(EBNA1)	mononucleosis	virus (EBV) Nuclear Antigen	control material in Nuclear Antigen	Nuclear Antigen (EBNA1)	(Nuclear Antigen (EBNA1)) antibodies in	=
		(EDIVAT)		(EBNA1) Protein	(EBNA1) level test of Infectious	mouse monoclonal antibody	Nuclear Antigen (EBNA1) level test of Infectious	
					disease(infectious mononucleosis) and	(mAb)	disease (infectious mononucleosis) and related	
					related syndrome evaluation.		syndrome evaluation.	
					Epstein-Barr virus (capsid antigen (EB-		Epstein-Barr virus (capsid antigen (EB-VCA))	
					VCA)) antibodies binding, Immunogen	GMP-IVD-P033-Tg002-Ab01;	antigen binding, ELISA validated as capture	
				GMP-IVD-P033-Tg002-Ag01:	in Sandwich Elisa, lateral-flow tests,and	GMP-IVD-P033-Tg002-Ab02:	antibody and detection antibody. Pair	
GMP-IVD-	Epstein-Barr	capsid antigen	infectious	Recombinant Epstein-Barr	other immunoassays as control material	Anti-Epstein-Barr virus (EBV)	recommendation with other Epstein-Barr virus	_
P033-Tg002	virus (EBV)	(EB-VCA)	mononucleosis	virus (EBV) capsid antigen	in capsid antigen (EB-VCA) level test of	capsid antigen (EB-VCA)	(capsid antigen (EB-VCA)) antibodies in capsid	=
				(EB-VCA) Protein	Infectious disease(infectious	mouse monoclonal antibody	antigen (EB-VCA) level test of Infectious disease	,
					mononucleosis) and related syndrome	(mAb)	(infectious mononucleosis) and related	
					evaluation.		syndrome evaluation.	

For inquiry please click here to contact us or send email to support@genemedi.net

Vibrio cholerae (V. cholerae)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
					Vibrio cholerae (cytotoxin B (CtxB))	OMB IVID DOOR T AND ALL OLD	Vibrio cholerae (cytotoxin B (CtxB)) antigen	
					antibodies binding, Immunogen in	GMP-IVD-P035-Tg001-Ab01;	binding, ELISA validated as capture antibody	
				GMP-IVD-P035-Tg001-Ag01:	Sandwich Elisa, lateral-flow tests,and	GMP-IVD-P035-Tg001-Ab02:	and detection antibody. Pair recommendation	
GMP-IVD-	Vibrio cholerae	cytotoxin	Cholera	Recombinant Vibrio cholerae	other immunoassays as control material	Anti-Vibrio cholerae (V.	with other Vibrio cholerae (cytotoxin B (CtxB))	=
P035-Tg001	(V. cholerae)	B (CtxB)		(V. cholerae) cytotoxin	in cytotoxin B (CtxB) level test of	cholerae) cytotoxin B (CtxB)	antibodies in cytotoxin B (CtxB) level test of	
				B (CtxB) Protein	Infectious disease(Cholera) and related	mouse monoclonal antibody	Infectious disease (Cholera) and related	
					syndrome evaluation.	(mAb)	syndrome evaluation.	

Mycobacterium tuberculosis (M. tuberculosis)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
					Mycobacterium tuberculosis (M. tb)	GMP-IVD-P036-Tg001-Ab01;	Mycobacterium tuberculosis (M. tb) antigen	
	Mycobacterium			GMP-IVD-P036-Tg001-Ag01:	antibodies binding, Immunogen in	GMP-IVD-P036-Tg001-Ab02:	binding, ELISA validated as capture antibody	
014D II (D					Sandwich Elisa, lateral-flow tests,and		and detection antibody. Pair recommendation	
GMP-IVD-	tuberculosis	M. tb	Tuberculosis		other immunoassays as control material		with other Mycobacterium tuberculosis (M. tb)	=
P036-Tg001	(M.		(TB)	tuberculosis (M. tuberculosis)	in M. tb level test of Infectious	tuberculosis (M. tuberculosis)	antibodies in M. tb level test of Infectious	
	tuberculosis)			M. tb Protein	disease(Tuberculosis (TB)) and related	M. tb mouse monoclonal	disease (Tuberculosis (TB)) and related	
					syndrome evaluation.	antibody (mAb)	syndrome evaluation.	

For inquiry please click here to contact us or send email to support@genemedi.net

Cryptosporidium parvum (Cp23)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
					Cryptosporidium (Crypto) antibodies		Cryptosporidium (Crypto) antigen binding,	
					binding, Immunogen in Sandwich Elisa,	GMP-IVD-P037-Tg001-Ab01;	ELISA validated as capture antibody and	
CMD IVD	Compande a manifelia man			GMP-IVD-P037-Tg001-Ag01:	lateral-flow tests,and other	GMP-IVD-P037-Tg001-Ab02:	detection antibody. Pair recommendation with	
GMP-IVD-	Cryptosporidium	Crypto	cryptosporidiosis	Recombinant Cryptosporidium	immunoassays as control material in	Anti-Cryptosporidium parvum	other Cryptosporidium (Crypto) antibodies in	₩
P037-Tg001	parvum (Cp23)			parvum (Cp23) Crypto Protein	Crypto level test of Infectious	(Cp23) Crypto mouse	Crypto level test of Infectious disease	
					disease(cryptosporidiosis) and related	monoclonal antibody (mAb)	(cryptosporidiosis) and related syndrome	
					syndrome evaluation.		evaluation.	

For inquiry please click here to contact us or send email to support@genemedi.net

Respiratory syncytial virus (RSV)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-IVD- P038-Tg001	Respiratory syncytial virus (RSV)	major surface glycoproteins (G and F)	cold	GMP-IVD-P038-Tg001-Ag01: Recombinant Respiratory syncytial virus (RSV) major surface glycoproteins (G and F) Protein	Respiratory syncytial virus (major surface glycoproteins (G and F)) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays as control material in major surface glycoproteins (G and F) level test of Infectious disease(cold) and related syndrome evaluation.	GMP-IVD-P038-Tg001-Ab02: Anti-Respiratory syncytial virus (RSV) major surface glycoproteins (G and F) mouse monoclonal antibody	Respiratory syncytial virus (major surface glycoproteins (G and F)) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Respiratory syncytial virus (major surface glycoproteins (G and F)) antibodies in major surface glycoproteins (G and F) level test of Infectious disease (cold) and related syndrome evaluation.	=

For inquiry please click here to contact us or send email to support@genemedi.net

Rhinoviruses (RV)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
					Rhinoviruses (VP1) antibodies binding,	GMP-IVD-P039-Tg001-Ab01;	Rhinoviruses (VP1) antigen binding, ELISA	
				GMP-IVD-P039-Tg001-Ag01:	Immunogen in Sandwich Elisa, lateral-	GMP-IVD-P039-Tg001-Ab02:	validated as capture antibody and detection	
GMP-IVD-	Rhinoviruses	VP1	common cold	Recombinant Rhinoviruses	flow tests,and other immunoassays as	Anti-Rhinoviruses (RV) VP1	antibody. Pair recommendation with other	
P039-Tg001	(RV)	VFI	common colu	(RV) VP1 Protein	control material in VP1 level test of	mouse monoclonal antibody	Rhinoviruses (VP1) antibodies in VP1 level test	=
				(ITV) VI I I TOLEIII	Infectious disease(common cold) and	(mAb)	of Infectious disease (common cold) and related	I
					related syndrome evaluation.	(IIIAb)	syndrome evaluation.	
					Rhinoviruses (VP3) antibodies binding,	GMP-IVD-P039-Tg002-Ab01;	Rhinoviruses (VP3) antigen binding, ELISA	
				GMP-IVD-P039-Tg002-Ag01:	Immunogen in Sandwich Elisa, lateral-	GMP-IVD-P039-Tg002-Ab02:	validated as capture antibody and detection	
GMP-IVD-	Rhinoviruses	VP3	common cold	Recombinant Rhinoviruses	flow tests,and other immunoassays as	Anti-Rhinoviruses (RV) VP3	antibody. Pair recommendation with other	
P039-Tg002	(RV)	VIO	common colu	(RV) VP3 Protein	control material in VP3 level test of	mouse monoclonal antibody	Rhinoviruses (VP3) antibodies in VP3 level test	=
				(NV) VES FIOLEIII	Infectious disease(common cold) and	•	of Infectious disease (common cold) and related	I
					related syndrome evaluation.	(mAb)	syndrome evaluation.	

For inquiry please click here to contact us or send email to support@genemedi.net

dengue nonstructural 1 (DEN-NS1)

Cat No. Pathogen Target Disease Cat No.of Antigen Bioactivity validation of Antigen Cat No.	o.of Antibodies Bioactivity validation of Antibodies Order
---	--

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
					dengue nonstructural 1 (nonstructural		dengue nonstructural 1 (nonstructural protein 1	
				GMP-IVD-P040-Tg001-Ag01:	protein 1 (NS1)) antibodies binding,	GMP-IVD-P040-Tg001-Ab01;	(NS1)) antigen binding, ELISA validated as	
	dengue			Recombinant dengue	Immunogen in Sandwich Elisa, lateral-	GMP-IVD-P040-Tg001-Ab02:	capture antibody and detection antibody. Pair	
GMP-IVD-	nonstructural 1	nonstructural	dengue	nonstructural 1 (DEN-NS1)	flow tests,and other immunoassays as	Anti-dengue nonstructural 1	recommendation with other dengue	
P040-Tg001		protein 1 (NS1)	deligue		control material in nonstructural protein	(DEN-NS1) nonstructural	nonstructural 1 (nonstructural protein 1 (NS1))	=
	(DEN-NOT)			Protein	1 (NS1) level test of Infectious	protein 1 (NS1) mouse	antibodies in nonstructural protein 1 (NS1) level	1
					disease(dengue) and related syndrome	monoclonal antibody (mAb)	test of Infectious disease (dengue) and related	
					evaluation.		syndrome evaluation.	

Enterovirus 71-lgM (EV71-lgM)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-IVD- P041-Tg001	Enterovirus 71- IgM (EV71- IgM)	VP1	neurological diseases	GMP-IVD-P041-Tg001-Ag01: Recombinant Enterovirus 71- IgM (EV71-IgM) VP1 Protein	Enterovirus 71-IgM (VP1) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays as control material in VP1 level test of Infectious disease(neurological diseases) and related syndrome evaluation.	GMP-IVD-P041-Tg001-Ab01; GMP-IVD-P041-Tg001-Ab02: Anti-Enterovirus 71-IgM (EV71-IgM) VP1 mouse monoclonal antibody (mAb)	ELISA validated as capture antibody and	₩

For inquiry please click here to contact us or send email to support@genemedi.net

streptolysin O (SLO)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-IVD- P042-Tg001	streptolysin O (SLO)	streptolysin O	Streptococcus pyogenes infection	GMP-IVD-P042-Tg001-Ag01: Recombinant streptolysin O (SLO) streptolysin O Protein	Sandwich Elisa, lateral-flow tests,and	Anti-streptolysin O (SLO)	streptolysin O (streptolysin O) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other streptolysin O (streptolysin O) antibodies in streptolysin O level test of Infectious disease (Streptococcus pyogenes infection) and related syndrome evaluation.	=

For inquiry please click here to contact us or send email to support@genemedi.net

Mycoplasma pneumoniae

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Orde
GMP-IVD- P043-Tg001	Mycoplasma pneumoniae	M-P1-10	pneumonia	GMP-IVD-P043-Tg001-Ag01: Recombinant Mycoplasma pneumoniae M-P1-10 Protein	Mycoplasma pneumoniae P1 adhesion protein (M-P1-10) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays as control material in M-P1-10 level test of Infectious disease(pneumonia) and related syndrome evaluation.	Anti-Mycoplasma pneumoniae	Mycoplasma pneumoniae P1 adhesion protein (M-P1-10) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Mycoplasma pneumoniae P1 adhesion protein (M-P1-10) antibodies in M-P1-10 level test of Infectious disease (pneumonia) and related syndrome	

For inquiry please click here to contact us or send email to support@genemedi.net

Helicobacter pylori (H. pylori)

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
					Helicobacter pylori cytotoxin-related		Helicobacter pylori cytotoxin-related protein A	
					protein A (CagA) antibodies binding,	GMP-IVD-P044-Tg001-Ab01;	(CagA) antigen binding, ELISA validated as	
	Helicobacter			GMP-IVD-P044-Tg001-Ag01:	Immunogen in Sandwich Elisa, lateral-	GMP-IVD-P044-Tg001-Ab01;	capture antibody and detection antibody. Pair	
GMP-IVD-	pylori (H.	CagA	peptic ulcer and		flow tests,and other immunoassays as	Anti-Helicobacter pylori (H.	recommendation with other Helicobacter pylori	.
P044-Tg001	pylori)	CagA	gastritis	pylori (H. pylori) CagA Protein	control material in CagA level test of		cytotoxin-related protein A (CagA) antibodies in	1 =
	pylon			pylon (n. pylon) daga notelin	Infectious disease(peptic ulcer and	monoclonal antibody (mAb)	CagA level test of Infectious disease (peptic	
					gastritis) and related syndrome	monocional antibody (m/b)	ulcer and gastritis) and related syndrome	
					evaluation.		evaluation.	

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
					Helicobacter pylori flagellin A (FlaA)		Helicobacter pylori flagellin A (FlaA) antigen	
					antibodies binding, Immunogen in	GMP-IVD-P044-Tg002-Ab01;	binding, ELISA validated as capture antibody	
CMP IV/D	Helicobacter	Florellin A	mantia ulaan and	GMP-IVD-P044-Tg002-Ag01:	Sandwich Elisa, lateral-flow tests,and	GMP-IVD-P044-Tg002-Ab02:	and detection antibody. Pair recommendation	
GMP-IVD-	pylori (H.	Flagellin A	peptic ulcer and	Recombinant Helicobacter	other immunoassays as control material	Anti-Helicobacter pylori (H.	with other Helicobacter pylori flagellin A (FlaA)	=
P044-Tg002	pylori)	(FlaA)	gastritis	pylori (H. pylori) FlaA Protein	in FlaA level test of Infectious	pylori) FlaA mouse	antibodies in FlaA level test of Infectious disease	
					disease(peptic ulcer and gastritis) and	monoclonal antibody (mAb)	(peptic ulcer and gastritis) and related syndrome	!
					related syndrome evaluation.		evaluation.	
					Helicobacter pylori flagellin B (FlaB)		Helicobacter pylori flagellin B (FlaB) antigen	
					antibodies binding, Immunogen in	GMP-IVD-P044-Tg003-Ab01;	binding, ELISA validated as capture antibody	
	Helicobacter			GMP-IVD-P044-Tg003-Ag01:	Sandwich Elisa, lateral-flow tests,and	GMP-IVD-P044-Tg003-Ab02:	and detection antibody. Pair recommendation	
GMP-IVD-	pylori (H.	Flagellin B	peptic ulcer and	Recombinant Helicobacter	other immunoassays as control material	Anti-Helicobacter pylori (H.	with other Helicobacter pylori flagellin B (FlaB)	=
P044-Tg003	pylori)	(FlaB)	gastritis	pylori (H. pylori) FlaB Protein	in FlaB level test of Infectious	pylori) FlaB mouse	antibodies in FlaB level test of Infectious disease	
					disease(peptic ulcer and gastritis) and	monoclonal antibody (mAb)	(peptic ulcer and gastritis) and related syndrome	
					related syndrome evaluation.	,	evaluation.	
					Helicobacter pylori vacuolar cytotoxin A		Helicobacter pylori vacuolar cytotoxin A (Vac A)	
					(Vac A) antibodies binding, Immunogen	GMP-IVD-P044-Ta004-Ab01:	antigen binding, ELISA validated as capture	
	Helicobacter			GMP-IVD-P044-Tg004-Ag01:	in Sandwich Elisa, lateral-flow tests,and		antibody and detection antibody. Pair	
GMP-IVD-		\/aa	peptic ulcer and					
P044-Tg004	pylori (H.	Vac A	gastritis	Recombinant Helicobacter	other immunoassays as control material	,	recommendation with other Helicobacter pylori	=
	pylori)			pylori (H. pylori) Vac A Protein	in Vac A level test of Infectious	pylori) Vac A mouse	vacuolar cytotoxin A (Vac A) antibodies in Vac A	
					disease(peptic ulcer and gastritis) and	monoclonal antibody (mAb)	level test of Infectious disease (peptic ulcer and	
					related syndrome evaluation.		gastritis) and related syndrome evaluation.	
					Helicobacter pylori urease B (Ure B)		Helicobacter pylori urease B (Ure B) antigen	
					antibodies binding, Immunogen in	GMP-IVD-P044-Tg005-Ab01;	binding, ELISA validated as capture antibody	
GMP-IVD-	Helicobacter		peptic ulcer and	GMP-IVD-P044-Tg005-Ag01:	Sandwich Elisa, lateral-flow tests,and	GMP-IVD-P044-Tg005-Ab02:	and detection antibody. Pair recommendation	
P044-Tg005	pylori (H.	Ure B	gastritis	Recombinant Helicobacter	other immunoassays as control material	Anti-Helicobacter pylori (H.	with other Helicobacter pylori urease B (Ure B)	=
3	pylori)		Januaria	pylori (H. pylori) Ure B Protein	in Ure B level test of Infectious	pylori) Ure B mouse	antibodies in Ure B level test of Infectious	
					disease(peptic ulcer and gastritis) and	monoclonal antibody (mAb)	disease (peptic ulcer and gastritis) and related	
					related syndrome evaluation.		syndrome evaluation.	
					Helicobacter pylori heat shock protein		Helicobacter pylori heat shock protein (HSP)	
					(HSP) antibodies binding, Immunogen	GMP-IVD-P044-Tg006-Ab01;	antigen binding, ELISA validated as capture	
CMD IVD	Helicobacter		nentic ulcer and	GMP-IVD-P044-Tg006-Ag01:	in Sandwich Elisa, lateral-flow tests,and	GMP-IVD-P044-Tg006-Ab02:	antibody and detection antibody. Pair	
GMP-IVD-	pylori (H.	HSP	peptic ulcer and	Recombinant Helicobacter	other immunoassays as control material	Anti-Helicobacter pylori (H.	recommendation with other Helicobacter pylori	=
P044-Tg006	pylori)		gastritis	pylori (H. pylori) HSP Protein	in HSP level test of Infectious	pylori) HSP mouse	heat shock protein (HSP) antibodies in HSP	
					disease(peptic ulcer and gastritis) and	monoclonal antibody (mAb)	level test of Infectious disease (peptic ulcer and	
					related syndrome evaluation.		gastritis) and related syndrome evaluation.	
					Helicobacter pylori outer membrane		Helicobacter pylori outer membrane protein 1	
					protein 1 (OMP-1) antibodies binding,		(OMP-1) antigen binding, ELISA validated as	
		outer		GMP-IVD-P044-Tg007-Ag01:	Immunogen in Sandwich Elisa, lateral-	GMP-IVD-P044-Tg007-Ab01;	capture antibody and detection antibody. Pair	
GMP-IVD-	Helicobacter	membrane	peptic ulcer and	Recombinant Helicobacter	flow tests,and other immunoassays as	GMP-IVD-P044-Tg007-Ab02:	recommendation with other Helicobacter pylori	
P044-Tg007	pylori (H.	protein 1	gastritis	pylori (H. pylori) OMP-1	control material in OMP-1 level test of	Anti-Helicobacter pylori (H.	outer membrane protein 1 (OMP-1) antibodies in	=
	pylori)	(OMP-1)		Protein	Infectious disease(peptic ulcer and	pylori) OMP-1 mouse	OMP-1 level test of Infectious disease (peptic	
		, ,			gastritis) and related syndrome	monoclonal antibody (mAb)	ulcer and gastritis) and related syndrome	
					evaluation.		evaluation.	
					Helicobacter pylori outer membrane		Helicobacter pylori outer membrane protein 3	
					protein 3 (OMP-2) antibodies binding,		(OMP-2) antigen binding, ELISA validated as	
		outer		GMP-IVD-P044-Tg008-Ag01:	Immunogen in Sandwich Elisa, lateral-	GMP-IVD-P044-Tg008-Ab01;	capture antibody and detection antibody. Pair	
CMD IVD	Helicobacter		nentic ulcor and			GMP-IVD-P044-Tg008-Ab02:		
GMP-IVD-	pylori (H.	membrane	peptic ulcer and	Recombinant Helicobacter	flow tests,and other immunoassays as	Anti-Helicobacter pylori (H.	recommendation with other Helicobacter pylori	=
P044-Tg008	pylori)	protein 2	gastritis	pylori (H. pylori) OMP-2	control material in OMP-2 level test of	pylori) OMP-2 mouse	outer membrane protein 3 (OMP-2) antibodies in	
		(OMP-2)		Protein	Infectious disease(peptic ulcer and	monoclonal antibody (mAb)	OMP-2 level test of Infectious disease (peptic	
					gastritis) and related syndrome		ulcer and gastritis) and related syndrome	
					evaluation.		evaluation.	

Prion								
Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-IVD- P045-Tg001	Prion	PrP	Transmissible spongiform encephalopathies	GMP-IVD-P045-Tg001-Ag01: Recombinant Prion PrP Protein	Prion (PrP) antibodies binding, Immunogen in Sandwich Elisa, lateral- flow tests,and other immunoassays as control material in PrP level test of Infectious disease(Transmissible spongiform encephalopathies) and related syndrome evaluation.	GMP-IVD-P045-Tg001-Ab01;	Prion (PrP) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Prion (PrP) antibodies in PrP level test of Infectious disease (Transmissible spongiform encephalopathies) and related syndrome evaluation.	=

STDs

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
					Sexually transmitted diseases (STDs)		Sexually transmitted diseases (STDs) antigen	
					antibodies binding, Immunogen in	GMP-IVD-P046-Tg001-Ab01;	binding, ELISA validated as capture antibody	
GMP-IVD-			Sexually	GMP-IVD-P046-Tg001-Ag01:	Sandwich Elisa, lateral-flow tests,and	GMP-IVD-P046-Tg001-Ab01;	and detection antibody. Pair recommendation	
P046-Tg001	NA	STDs	transmitted		other immunoassays as control material		with other Sexually transmitted diseases (STDs)) 🛒
F040-19001			diseases	Recombinant 31Ds Flotein	in STDs level test of Infectious	antibody (mAb)	antibodies in STDs level test of Infectious	
					disease(Sexually transmitted diseases)	antibody (mab)	disease (Sexually transmitted diseases) and	
					and related syndrome evaluation.		related syndrome evaluation.	

For inquiry please click here to contact us or send email to support@genemedi.net

ARTI

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
					acute respiratory infectious diseases		acute respiratory infectious diseases (ARTI)	
					(ARTI) antibodies binding, Immunogen		antigen binding, ELISA validated as capture	
			acuta recoiratory		in Sandwich Elisa, lateral-flow tests,and	GMP-IVD-P047-Tg001-Ab01;	antibody and detection antibody. Pair	
GMP-IVD-	NA		acute respiratory infectious		other immunoassays as control material	GMP-IVD-P047-Tg001-Ab02:	recommendation with other acute respiratory	
P047-Tg001	INA	ARTI	diseases	Recombinant ARTI Protein	in ARTI level test of Infectious	Anti-ARTI mouse monoclonal	infectious diseases (ARTI) antibodies in ARTI	=
			uiseases		disease(acute respiratory infectious	antibody (mAb)	level test of Infectious disease (acute respiratory	y
					diseases) and related syndrome		infectious diseases) and related syndrome	
					evaluation.		evaluation.	

For inquiry please click here to contact us or send email to support@genemedi.net

SARS-CoV2

Cat No.	Pathogen	Target	Disease	Cat No.of Antigen	Bioactivity validation of Antigen	Cat No.of Antibodies	Bioactivity validation of Antibodies	Order
GMP-IVD- P049-Tg001	SARS-CoV2	Nucleocapsid	COVID-19	GMP-IVD-P048-Tg001-Ag01: Recombinant SARS-CoV2 Nucleocapsid Protein	SARS-CoV2 Nucleocapsid antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays as control material in Nucleocapsid level test of Infectious disease(COVID-19) and related syndrome evaluation.	GMP-IVD-P048-Tg001-Ab01; GMP-IVD-P048-Tg001-Ab02: Anti-SARS-CoV2 Nucleocapsid mouse monoclonal antibody (mAb)	SARS-CoV2 Nucleocapsid antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other SARS-CoV2 Nucleocapsid antibodies in Nucleocapsid level test of Infectious disease (COVID-19) and related syndrome evaluation.	=

For inquiry please click here to contact us or send email to support@genemedi.net

EC50(TU/

ml)

3.5x10⁶

1.9x10⁶

 $0.75x10^6$




Figure. GeneMedi and other company's P24 antibody pairs validation with HIV PSV (GMVP-LVc10) in sandwich ELISA. GeneMedi's P24 antibody pair has a larger linear range and better sensitivity, and represents the best EC50. GeneMedi's Ab01: GMP-HIV1-Ab01, GeneMedi's Ab02: GMP-HIV1-Ab02.

Abstract

Infectious diseases are a significant burden on public health and economic stability of societies all over the world. They have been among the leading causes of death and disability and presented growing challenges to health security and human progress for centuries. Infectious diseases are generally caused by microorganisms. The routes of them entry into host is mostly by the mouth, eyes, genital openings, nose, and the skin. Damage to tissues mainly results from the growth and metabolic processes of infectious agents intracellular or within body fluids, with the production and release of toxins or enzymes that interfere with the normal functions of organs and/or systems [1]. Advances in basic science research and development of molecular technology and diagnostics have enhanced understanding of disease etiology, pathogenesis, and molecular epidemiology, which provide basis for appropriate detection, prevention, and control measures as well as rational design of vaccine [2]. The diagnosis of infectious diseases is particularly critical for the prevention and control of the epidemic. Here we introduce the insights and detection methods of infectious disease, aiming to provide some helps for clinical diagnosis as well as epidemic prevention and control of infectious diseases.

1. Introduction of human infectious diseases caused by living pathogens

Infectious diseases arise upon contact with an infectious agent. Five major infectious agents have been identified: bacteria, viruses, fungi, protozoans and parasites [3, 4]. Various factors can be identified that create opportunities for infectious agents to invade human hosts. These include global urbanization, increase in population density, poverty, social unrest, travel, land clearance, farming, hunting, keeping domestic pets, deforestation, climate change, and other human activities that destroy microbial habitat [5, 6]. Human engagement in activities that interfere with ecological and environmental conditions continues, thereby increasing the risk of contact with new pathogens. These pathogens are mostly transmitted though intermediate animal hosts such as rodents [7, 8], which gain increased contact with humans as a result of environmental and human behavioral factors. In most cases, a combination of risk factors accounts for infectious disease emergence and/or outbreak of epidemic. Here we list some past emerging infectious disease epidemics and probable factors for the outbreak in Table 1.

Table1. Some past infectious disease epidemics and possible outbreak factors

Year	Emerging disease	•	Main probable factor	Genemedi's diagnostic antibodies and antigens
теаг	Emerging disease	Pathogenic agent	Main probable factor	Genemeur's diagnostic antibodies and antigens
2019	2019-novel-coronavirus pneumonia	2019-nCoV/SARS-CoV-2	Dynamic balances and imbalances, within complex globally distributed ecosystems comprising humans, animals, pathogens, and the environment. May be because of hunting and feeding on infected wild animals (viverrids)	Antigens: Nucleocapsid (N protein), Spike(S protein), RBD, S1+S2 ECD, Envelope (E protein), 3C-like Proteinase (Mpro), RdRP(Nsp12), etc. Antibodies: N protein antibody (GMP-V-2019nCoV-NAb001~004), Spike protein antibody (GMP-V-2019nCoV-SAb001~004)
1976-2020	Ebola haemorrhagic fever	Filovirus Ebola virus	Rainforest penetration by humans/close contact with infected game (hunting) or with host reservoirs (bats)/infected biological products/nosocomial/needle spread	Antibodies: Anti-ebola virus (EV) nucleoprotein (NP) mouse monoclonal antibody (mAb) Antigens: Recombinant ebola virus (EV) nucleoprotein (NP) Protein
1889, 1890, 1918, 1957	Pandemic Influenza	Paramyxovirus influenza A	Animal-human virus reassortment and antigenic shift	Antibodies: Anti-Influenza A NP mouse monoclonal antibody Antigens: Recombinant Influenza A NP Protein (Flu A/B, His Tag)
2003	Severe acute respiratory syndrome (SARS)	SARS Coronavirus	Hunting and feeding on infected wild animals (viverrids)	
1997	Highly pathogenic avian influenza (HPAI)	H5N1 virus	Animal-animal influenza virus gene reassortment; emergence of H5N1 avian influenza, extensive chicken farming	Antibodies: Anti-Avian Influenza Virus Type A H5N1 subtype Nucleocapsid Protein (NP) mouse monoclonal antibody (mAb) Anti-Avian Influenza Virus Type A H5N1 subtype Haemagglutinin (HA) mouse monoclonal antibody (mAb) Antigens: Recombinant Avian Influenza Virus Type A H5N1 subtype NP Protein Recombinant Avian Influenza Virus Type A H5N1 subtype Haemagglutinin (HA) Protein
1996	Haemorrhagic colitis	Escherichia coli O157:H7	Ingestion of contaminated food, undercooked beef, and raw milk	
1988	Herpes	Herpes simplex virus 1/2(HSV-1/HSV-2)	Indirect contact transmission, saliva, liquid from herpes, blood,mother to baby at birth.	Antibodies: Anti-herpes simplex virus (HSV) mouse monoclonal antibody (mAb) Antigens: Recombinant herpes simplex virus (HSV) Protein
1987	Rift Valley fever (RVF)	Bunyavirus RVF virus	Dramatic increase in mosquito vector breeding sites (by dam filling); weather (rainfall) and cattle migration (guided by artificial water holes)	Antibodies: Anti-Rift Valley Fever (RVF) nucleoprotein (NP) mouse monoclonal antibody (mAb) Antigens: Recombinant Rift Valley Fever (RVF) nucleoprotein (NP) Protein
1987	Hepatitis C	Hepatitis c virus (HCV)	Blood, acupuncture, drug taking, etc	Antibodies: Anti-hepatitis C virus (HCV) Recombinant HCV NS3-NS4-NS5 fusion Protein (His Tag) mouse monoclonal antibody (mAb) Antigens: Recombinant hepatitis C virus (HCV) Recombinant HCV NS3-NS4-NS5 fusion Protein (His Tag) Protein
1983	Crimean-Congo haemorrhagic fever	CCHF virus	Ecological changes favouring increased human exposure to ticks of sheep and small wild animals	
1981	Acquired immunodeficiency syndrome (AIDS)	Human immunodeficiency virus (HIV)	Sexual contact/exposure to blood or tissues of an infected person	Antibodies: Anti-Human immunodeficiency virus 1 (HIV-1) GP41 Protein mouse monoclonal antibody (mAb) Antigens: Recombinant Human immunodeficiency virus 1 (HIV-1) GP41 Protein Protein


1976	Malaria	Plasmodium falciparum	Human behaviour/rainfall and drainage	Antigens: Recombinant Plasmodium merozoite surface protein (MSP) Protein
			problems/mosquito breeding/neglect of	Recombinant Plasmodium Circumsporozoite Protein (CSP) Protein
			eradication policy, economics, and	Antibodies: Anti-Plasmodium merozoite surface protein (MSP) mouse monoclonal
			growing interchange of populations	antibody (mAb)
				Anti-Plasmodium Circumsporozoite Protein (CSP) mouse monoclonal antibody
				(mAb)
1969	Lassa fever	Arenavirus Lassa virus	Hospital exposure to index case—rodent	
1303	Lassa level	Alchavirus Lassa virus	exposure	
				Antigens: Recombinant Hepatitis b virus (HBV) HBsAg Protein
				Recombinant Hepatitis B virus (HBV) HBeAg Protein
1965	Hepatitis B	Hepatitis b virus (HBV)	sexual contact, sharing needles, syringes, or other	Recombinant Hepatitis B virus (HBV) HBcAg Protein
1303	riepaniis D	riopatitis b virus (ribv)	drug-injection equipment, mother to baby at birth.	Antibodies: Anti-Hepatitis B virus (HBV) HBsAg mouse monoclonal antibody (mAb)
				Anti-Hepatitis B virus (HBV) HBeAg mouse monoclonal antibody (mAb)
				Anti-Hepatitis B virus (HBV) HBcAg mouse monoclonal antibody (mAb)
1959	Bolivian haemorrhagic fever	ArenavirusMachupo virus	Population increase of rats gathering food	
1000	(BHF)	7 ii onavii aoinaonapa vii ao	r opaliation moreage of rate gathering recu	
1958	Argentine haemorrhagic fever	ArenavirusJunin virus	Changes in agricultural practices of corn harvest	
1330	Argentine naemormagic rever	Archavilusuuriiri vilus	(maize mechanization)	
	Dengue haemorrhagic fever		Increasing human population density in	
1953		Dengue viruses 1, 2, 3, and 4	cities in a way that favours vector	
	(DHF)		breeding sites (water storage)	
				Antibodies: Recombinant Human papilloma virus (HPV) HPV 16 L1 capsid protein
1949	Cervical cancer	Human papilloma virus (HPV)	Contact infection, Sexual contact	Protein
1949	Cervical Caricer	Truman papilionia virus (HPV)	Contact infection, Sexual contact	Antibodies: Anti-Human papilloma virus (HPV) HPV 16 L1 capsid protein mouse
				monoclonal antibody (mAb)

2. The strategies used in diagnosis of human Infectious diseases

2.1 Molecular Methods

The development of molecular methods for the direct identification of a specific viral genome from the clinical sample is one of the greatest achievements of the 21st century. Clearly nucleic acid amplification techniques including Reverse Transcription-Polymerase Chain Reaction (RT-PCR), nucleic acid sequence-based amplification (NASBA) and Lawrence Livermore Microbial Detection Array (LMDA) are proven technology leaders for rapid detection and molecular identification for most known human viruses [9].

RT-PCR assays for virus detection provides faster results than end-point assays and in many cases have sensitivities equal to or better than culture [10]. The novel coronavirus, 2019-nCoV, was detected through real-time RT-PCR with primers against two segments of its RNA genome [11]. The particular primer sets and specific guideline for detection of COVID-19 through RT-PCR were made available by the Center for Disease Control (CDC) USA, according to CDC [12]. However, high mutation rates may lead to extensive changes in viral nucleic acid sequences making dedicated PCR primer use irrelevant, therefore there is high demand for the development of rapid and universal virus identification and detection technologies. In contrast, although NASBA assay is considered sensitive; it has not been widely used because of the difficulties in the preparation of NASBA master mix in-house and the high cost of commercial kits. A new molecular biology-based microbial detection method for rapid identification of multiple virus types in the same sample has been developed by a research group at Lawrence Livermore National Laboratory. Lawrence Livermore Microbial Detection Array (LLMDA) detects viruses using probes against genomic DNA sequence within 24 hours [13,14]. In addition, the oligonucleotide probes were selected to enable detection of novel, divergent species with homology to sequenced organisms [14].



2.2 Immuno-assays

The nucleic acid diagnostic tool currently employed is with good sensitivity and excellent specificity. However, due to its high false negative, time-consuming, high level equipment and technical personnel demand, the immunological antigen or antibody detection has been paid more and more attention because of its quick detection speed, low and simple technical requirements of detection. At present, the detection methods mainly include Enzyme-linked immunosorbent assays (ELISAs), colloidal gold immunochromatography (GICA) and magnetic

2.2.1 Enzyme-Linked Immunosorbent Assays (ELISA)

Enzyme-linked immunosorbent assays (ELISAs) incorporate the sensitivity of simple enzyme assays with the specificity of antibodies, by employing antigens or antibodies coupled to an easily-assayed enzyme. As such ELISA is much more rapid method than immunoblotting to detect specific viral protein from a cell, tissue, organ, or body fluid. There are two main variations of ELISAs: antigen-capture ELISA (detecting viral proteins), involve attachment of a capture antibody to a solid matrix for the viral protein of interest, while antibody-capture ELISA measures the specific antibody level in a sample, by coating viral antigen protein on a solid surface. There are two principles based on antigen-capture and antibody-capture ELISAs. In a general, ELISAs are considered a highly sensitive method that can detect a fairly low number of proteins at the range of picomolar to nanomolar range (10-12 to 10-9 moles per liter). ELISA has been one of the most widely used serologic tests for detecting antibody to HIV-1. ELISA method was found useful as a diagnostic tool to detect influenza viral antigen much quicker than other conventional virus detection methods [15]. In another previous study, comparison of ELISA, with conventional methods has demonstrated ELISA superiority for the rapid detection and identification of influenza A virus [16]. A simplified and standardized neutralization enzyme immunoassay (Nt-EIA) was developed to detect measles virus growth in Vero cells and to quantify measles neutralizing antibody [17]. Newer EIA formats for hepatitis C virus diagnostics have been constantly evaluated [18,19]. As such ELISAs are being used for plethora of application both in experimental and diagnostic virology including HIV-1, dengue, and influenza [20-22]. On the other hand, although rapid than traditional plaque assays or TCID50, ELISA assays sometimes could be quite expensive, due to the cost of reagents used. Unfortunately, sometimes required antibodies may not be commercially developed as well. In contrast, attempts to




Figure 2. A schematic representation of two principles based on antigen or antibody capture ELISA^[23]

2.2.2 Colloidal gold immunochromatography (GICA)

Based on the specific immune response of antigen and antibody, colloidal gold particles were used as one of the tracer markers. Driven by solvent chromatography, the markers had an immune response on the C/T line, and the detection results could be obtained according to the color of the T line. GICA samples can be whole blood, serum or plasma, and studies have shown that the colloidal gold reagent has a high consistency in detecting whole blood, plasma or serum [24]. At present, there are seven kinds of colloidal gold kits approved by the State Food and Drug Administration, which are all detection antibodies, but there is no detection kit for antigens. RT-PCR was used as the control method, and the sensitivity and specificity of IgM/IgG antibody were different, and the highest detection rate of the two combined detection was 66.1% (125/189) [25]. This method can be used for enterprise resumption, students return to school, community crowd screening and other scenarios. Only a drop of fingertip blood is needed, and the detection results can be observed visually in 15 minutes, which is rapid and simple without special instruments. However, the detection has its disadvantages such as window period, without quantification, exposure risk, low sensitivity and vulnerability to environmental factors, and nucleic acid detection combination result is required for verification.




Figure 3. Scheme showing the general steps in the antibody-based diagnosis of viral infections from blood samples^[26]

2.2.3 Magnetic particle chemiluminescence

Magnetic particle chemiluminescence is an emerging technique to capture specific IgM/IgG antibodies in samples using magnetic particles fixed on the surface of recombinant antigens. The antigen-antibody complex was precipitated by external magnetic field, and the captured antigen-antibody complex was identified by enzyme-labeled secondary antibody, and the luminescent intensity was determined by chemiluminescence instrument after adding the luminescent agent, and then quantitative analysis was carried out. It is characterized by high sensitivity, high specificity and wide detection range, etc. There are currently seven approved magnetic particle chemiluminescence detection kits, the first one developed by Bioscience, with an automatic chemiluminescence analyzer, capable of detecting at a speed of 240 T/H with an initial reporting time of 30 min [27].

2.3 Viral Culture

Virus culture, isolation and identification are the gold standards for laboratory identification of pathogens. However, viral culture results do not yield timely results to inform clinical management. Shell-vial tissue culture results may take 1-3 days, while traditional tissue-cell viral culture results may take 3-10 days. Due to the long incubation time, high technical requirements, and must be carried out in a level III safe biological laboratory, it is not suitable for rapid virus diagnosis during the epidemic period [28].

2.4 Immunofluorescence (IF) Assay

Immunofluorescence (IF) technique is widely used for rapid detection of virus infections by identifying virus antigens in clinical specimens. IF staining is usually considered very rapid (about 1 to 2 hr) and overall gives a sensitive and specific viral identification [29-32]. Unfortunately, IF technique may not able to confirm the identity of all virus strains, for instance viruses of the "enterovirus" group; since most monoclonal antibodies (MAbs) for enteroviral identification have been shown to lack sensitivity, while cross-reactivity with rhinoviruses is extremely common [33]. In contrast, IF has been successfully used for better management of influenza virus infection and surveillance of influenza virus activity [30, 31]. As recommended by CDC, when influenza activity is low, positive results should be confirmed by direct immunofluorescence assay (DFA), viral culture, or RT-PCR, as false positive test results are more likely; while during peak influenza activity confirmatory testing using DFA, viral culture, or PCR must always be considered because a negative test may not rule out influenza viral infection. Interestingly, although IF is generally considered less sensitive then ELISA and PCR, a recent publication reports DFA as an optimal method for rapid identification of varicella-zoster virus (VZV), when compared with conventional cell culture [34]. In contrast, the Herpes simplex virus (HSV) DFA test accuracy was found very low (sensitivity 61%, specificity 99%), when tested to identify mucocutaneous HSV infection in children [35]. Furthermore, a monoclonal antibody designated CHA 437 was developed against HSV showed no cross-reactivity against the varicella-zoster virus, cytomegalovirus, or Epstein-Barr virus, however direct specimen testing resulted in overall low sensitivity (84.6%) and specificity (95.7%) [36]. On the other hand, an antigen detection assay for severe acute respiratory syndrome (SARS) coronavirus (CoV) could detect SARS-CoV in 11 out of 17 (65%) samples from SARS patients. As such I

As such IF technique is well-accepted laboratory diagnostics test, however, sometime these assays could be quite expensive, due to the cost of antibodies used. Additional variability may also be introduced due to non-specific binding, or cross-reactivity of commercially available antibodies.




Figure 4. Immunofluorescence staining of vaccinia virus infected cell [38]. Areas of virus assembly within the cell are pink. Host and viral DNA (deoxyribonucleic acid) is blue. The host cell's DNA is contained within its nucleus (large oval). Actin protein filaments, which make up part of the cytoskeleton, are green.

2.5 Immunoblotting (WB)

Immunoblotting technique detects specific viral proteins isolated from a cell, tissue, organ, or body fluid. The development of sensitive and specific tests for human immunodeficiency virus type 1 (HIV-1) progressed rapidly after this retrovirus was found to be responsible for causing AIDS [39]. Immunoblotting has been one of the reference confirmatory tests for the diagnosis of HIV infection or after inconclusive enzyme immunoassay (EIA) results. Although difficulty in interpretation of immunoblotting results and the cost led to a reduction in overall use of WB technique, nevertheless immunoblots are still commonly used for various purposes, including clinical diagnosis of HIV-1, seroprevalence surveys, and for blood-donor screening. In addition, immunoblot assays have been used to confirm the anti-hepatitis C virus (HCV) reactivity [40]. In recent years immunoblotting has been established as an important prerequisite for the functional studies to understand protein composition of the purified viral particles, since it allows the analysis of specific proteins which result in better understanding of the infection process and the pathogenesis of viruses [41,42].

2.6 Transmission Electron Microscopy (TEM)

Most viruses are very small to be seen directly under a light microscope, and therefore could only be viewed with TEM (transmission electron microscopy). In 1948, smallpox and chicken pox were first differentiated by TEM [43] and thereafter early virus classifications depended heavily on TEM analysis. In particular many intestinal viruses were discovered by negative staining TEM microscopy [44, 45]. Although TEM has gradually been replaced by more sensitive methods such as PCR, nevertheless it still remains essential for several aspects of virology including discovery, description and titration of viruses. One of the major advantages of using TEM is that it does not require virus-specific reagents; this is of particular importance in an outbreak setting where the etiologic agent is unknown and therefore specific reagents may not be available to determine correct detection tests. Negative stained TEM technique continues to be a valuable tool for the discovery and identification of novel viruses including Ebola virus, henipavirus (Hendra and Nipah) and SARS [46-50]. A human monkeypox outbreak was detected in the US by TEM [51]. Nevertheless, due to the high instrument cost and the amount of space and facilities required, TEM is still only available in certain facilities.




Figure 5. Transmission Electron Microscopy of hantavirus virions^[52]

Summary

Infectious diseases are a real public health threat, outbreaks can have serious social, political, and economic effects. A complex number of factors relating to human behavior and activities, pathogen evolution, poverty, and changes in the environment as well as dynamic human interactions with animals have been found to contribute to infectious disease emergence and transmission. Aggressive research is warranted to unravel important characteristics of pathogens necessary for diagnostics, therapeutics, and vaccine development. Here we describe some strategies for the diagnosis of human infectious diseases, hoping to be helpful for clinical diagnosis and epidemic prevention and control of infectious diseases. To date, multiple diagnostic techniques have been developed. Various diagnostic tools show both significances and limitations. Conventional approaches to quantify infective viral particles are labor-intensive, timeconsuming, and often associated with poor reproducibility. Immunological tests generally provide quick results, however, is quite expensive due to the requirement of antigen-specific antibody. While RT-PCR may be able to provide results within a matter of hours, it is laborious, requires a skilled operator, and is sensitive to contamination. TEM-based quantification, although highly accurate in determining the shape and the total number of viral particles, often considered time-consuming, extremely expensive and impractical for high sample numbers. Moreover, TEM sample preparation is tedious, and the technique requires sophisticated instrument and a skilled operator. To alleviate these limitations, there is still a need to develop new cost-effective analytical methods that can allow users to quickly and easily determine virus concentrations and reduce constrictions coupled with current assays. Nevertheless, any such emerging methods must be carefully evaluated in terms of their efficiency, precision and linear range. The evaluation of each diagnostic technique and approval from the FDA are necessary before practical application.

Reference

- [1] National Institutes of Health (US) and BSC Study, Understanding Emerging and Re-emerging Infectious Diseases, National Institutes of Health (US), 2007.
- [2] Nii-Trebi NI. Emerging and Neglected Infectious Diseases: Insights, Advances, and Challenges. Biomed Res Int. 2017; 2017:5245021. doi: 10.1155/2017/5245021. Epub 2017 Feb 13. PMID: 28286767; PMCID: PMC5327784.
- [3] N. C. Barber and L. A. Stark, "Online resources for understanding outbreaks and infectious diseases," CBE Life Sciences Education, vol. 14, no. 1, 2015.
- [4] "Globalization and infectious diseases: a review of the linkages," http://www.who.int/tdr/publications/documents/seb topic3.pdf.
- [5] S. S. Morse, "Factors and determinants of disease emergence," OIE Revue Scientific et Technique, vol. 23, no. 2, pp. 443–451, 2004.
- [6] A. Tadin, R. Tokarz, A. Markotic et al., "Molecular survey of zoonotic agents in rodents and other small mammals in Croatia," American Journal of Tropical Medicine and Hygiene, vol. 94, no. 2, pp. 466–473, 2016.
- [7] World Health Organization, "Infectious diseases: a manual for nurses and midwives in the WHO European Region," http://www.euro.who.int/ data/assets/pdf file/0013/102316/e79822.pdf.
- [8] S. S. Morse, J. A. K. Mazet, M. Woolhouse et al., "Prediction and prevention of the next pandemic zoonosis," The Lancet, vol. 380, no. 9857, pp. 1956–1965, 2012. [9] MATER METHODS 2013; 3:207
- [10] van Elden L, Nijhuis M, Schipper P, Schuurman R, van Loon A. Simultaneous detection of influenza viruses A and B using real-time quantitative PCR. J Clin Microbiol. 2001; 39:196-200
- [11] Corman V, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu D, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25 [12] Abbott. (2020b). ID NOWTM is a leading molecular point-of-care platform in the United States, trusted by hospitals, physician offices, and urgent care clinics nationwide. https://www.alere.com/en/home/product-details/idnow-covid-19.html
- [13] McLoughlin K. Microarrays for pathogen detection and analysis. Brief Funct Genomics. 2011; 10:342-53
- [14] Jaing C, Gardner S, McLoughlin K, Thissen J, Slezak T. Detection of adventitious viruses from biologicals using a broad-spectrum microbial detection array. PDA J Pharm Sci Technol. 2011; 65:668-74
- [15] Khanna M, Kumar P, Chugh L, Prasad A, Chhabra S. Evaluation of influenza virus detection by direct enzyme immunoassay (EIA) and conventional methods in asthmatic patients. J Commun Dis. 2001; 33:163-9 [16] Waner J, Todd S, Shalaby H, Murphy P, Wall L. Comparison of Directigen FLU-A with viral isolation and direct immunofluorescence for the rapid detection and identification of influenza A virus. J Clin Microbiol. 1991;
- [17] Lee M, Cohen B, Hand J, Nokes D. A simplified and standardized neutralization enzyme immunoassay for the quantification of measles neutralizing antibody. J Virol Methods. 1999; 78:209-17 [18] Kim M, Kang S, Lee W. Evaluation of a new rapid test kit to detect hepatitis C virus infection. J Virol Methods. 2013; 193:379-82
- [19] Niu X, Wang X, Liu G, Li Y. [Establishment of the evaluation reference system for domestic anti-hepatitis C virus diagnostic enzyme immunoassay kits]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2013; 29:761-4
- [20] Filice G, Soldini L, Orsolini P, Razzini E, Gulminetti R, Campisi D, et al. Sensitivity and specificity of anti-HIV ELISA employing recombinant (p24, p66, gp120) and synthetic (gp41) viral antigenic peptides. Microbiologica. 1991; 14:185-94
- [21] de Boer G, Back W, Osterhaus A. An ELISA for detection of antibodies against influenza A nucleoprotein in humans and various animal species. Arch Virol. 1990; 115:47-61
- [22] Cuzzubbo A, Vaughn D, Nisalak A, Solomon T, Kalayanarooj S, Aaskov J, et al. Comparison of PanBio dengue duo enzyme-linked immunosorbent assay (ELISA) and MRL dengue fever virus immunoglobulin M capture ELISA for diagnosis of dengue virus infections in Southeast Asia. Clin Diagn Lab Immunol. 1999; 6:705-12
- [23] https://www.virology.ws/2010/07/16/detection-of-antigens-or-antibodies-by-elisa/
- [24] Zhang WJ, Lv X, Huang C, et al. Clinical evaluation and application of detection of IgM and IgG antibodies against
- SARS-CoV-2 using a colloidal gold immunochromatography assay [J]. Chinese Journal of Virology, 2020, 36 (3): 348-354.
- [25] Li H, Li YY, Zhang ZG, et al. Establishment and clinical performance evaluation of 2019 novel coronavirus antibody colloidal gold detection method [J]. Chinese Journal of Infectious Diseases, 2020, 38 (3): 139-144. [26] Augustine R, Das S, Hasan A, S A, Abdul Salam S, Augustine P, Dalvi YB, Varghese R, Primavera R, Yassine HM, Thakor AS, Kevadiya BD. Rapid Antibody-Based COVID-19 Mass Surveillance: Relevance, Challenges, and Prospects in a Pandemic and Post-Pandemic World. J Clin Med. 2020 Oct 21;9(10):3372. doi: 10.3390/jcm9103372. PMID: 33096742; PMCID: PMC7589650.
- [27] LI Jia-jun, ZHENG Xiao, et al. Novel Coronavirus and Research Progress of Related Clinical Detection Methods [J]. Biotechnology Bulletin, ISSN 1002-5464, CN 11-2396/Q.
- [28] Timothy M Uyeki, Henry H Bernstein, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza, Clinical Infectious Diseases, Volume 68, Issue 6, 15 March 2019, Pages e1-e47, https://doi.org/10.1093/cid/ciy866
- [29] Anestad G. Surveillance of respiratory viral infections by rapid immunofluorescence diagnosis, with emphasis on virus interference. Epidemiol Infect. 1987; 99:523-31 [30] Daisy J, Lief F, Friedman H. Rapid diagnosis of influenza A infection by direct immunofluorescence of nasopharyngeal aspirates in adults. J Clin Microbiol. 1979; 9:688-92
- [31] Johnson J, Higgins A, Navarro A, HUANG Y, Esper F, Barton N, et al. Subtyping influenza A virus with monoclonal antibodies and an indirect immunofluorescence assay. J Clin Microbiol. 2012; 50:396-400 [32] Fauvel M, Ozanne G. Immunofluorescence assay for human immunodeficiency virus antibody: investigation of cell fixation for virus inactivation and antigen preservation. J Clin Microbiol. 1989; 27:1810-3
- [33] Klespies S, Cebula D, Kelley C, Galehouse D, Maurer C. Detection of enteroviruses from clinical specimens by spin amplification shell vial culture and monoclonal antibody assay. J Clin Microbiol. 1996; 34:1465-7
- [34] Coffin S, Hodinka R. Utility of direct immunofluorescence and virus culture for detection of varicella-zoster virus in skin lesions. J Clin Microbiol. 1995; 33:2792-5
- [35] Caviness A, Oelze L, Saz U, Greer J, Demmler Harrison G. Direct immunofluorescence assay compared to cell culture for the diagnosis of mucocutaneous herpes simplex virus infections in children. J Clin Virol. 2010;
- [36] Pouletty P, Chomel J, Thouvenot D, Catalan F, Rabillon V, Kadouche J. Detection of herpes simplex virus in direct specimens by immunofluorescence assay using a monoclonal antibody. J Clin Microbiol. 1987; 25:958-9 [37] Liu I, Chen P, Yeh S, Chiang Y, Huang L, Chang M, et al. Immunofluorescence assay for detection of the nucleocapsid antigen of the severe acute respiratory syndrome (SARS)-associated coronavirus in cells derived from throat wash samples of patients with SARS. J Clin Microbiol. 2005; 43:2444-8
- [38] https://fineartamerica.com/featured/6-vaccinia-virus-infected-cell-dr-dan-kalman.html
- [39] Schochetman G, Epstein J, Zuck T. Serodiagnosis of infection with the AIDS virus and other human retroviruses. Annu Rev Microbiol. 1989; 43:629-59
- [40] Damen M, Zaaijer H, Cuypers H, Vrielink H, van der Poel C, Reesink H, et al. Reliability of the third-generation recombinant immunoblot assay for hepatitis C virus. Transfusion. 1995; 35:745-9 [41] Kong Q, Xue C, Ren X, Zhang C, Li L, Shu D, et al. Proteomic analysis of purified coronavirus infectious bronchitis virus particles. Proteome Sci. 2010; 8:29
- [42] Ren X, Xue C, Kong Q, Zhang C, Bi Y, Cao Y. Proteomic analysis of purified Newcastle disease virus particles. Proteome Sci. 2012; 10:32
- [43] Nagler F, Rake G. The Use of the Electron Microscope in Diagnosis of Variola, Vaccinia, and Varicella. J Bacteriol. 1948; 55:45-51
- [44] Gust I, Kaldor J, Cross G, Waugh M, Ferris A. Virus-like particles associated with a faecal antigen from hepatitis patients and with Australia antigen. Aust J Exp Biol Med Sci. 1971; 49:1-9
- [45] Kapikian A, Wyatt R, Dolin R, Thornhill T, Kalica A, Chanock R. Visualization by immune electron microscopy of a 27-nm particle associated with acute infectious nonbacterial gastroenteritis. J Virol. 1972; 10:1075-81
- [46] Johnson K, Lange J, Webb P, Murphy F. Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire. Lancet. 1977; 1:569-71
- [47] Pattyn S, van der Groen G, Jacob W, Piot P, Courteille G. Isolation of Marburg-like virus from a case of haemorrhagic fever in Zaire. Lancet. 1977; 1:573-4 [48] Chua K, Wong E, Cropp B, Hyatt A. Role of electron microscopy in Nipah virus outbreak investigation and control. Med J Malaysia. 2007; 62:139-42
- [49] Hyatt A, Zaki S, Goldsmith C, Wise T, Hengstberger S. Ultrastructure of Hendra virus and Nipah virus within cultured cells and host animals. Microbes Infect. 2001; 3:297-306
- [50] Drosten C, Gunther S, Preiser W, van der Werf S, Brodt H, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003; 348:1967-76
- [51] Reed K, Melski J, Graham M, Regnery R, Sotir M, Wegner M, et al. The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med. 2004; 350:342-50
- [52] https://www.hantasite.com/2017/03/hantavirus-life-cycle-and-infection.html



About us

GeneMedi

With strong expertise in Gene&Biogitics discovery, artificial design, and State-of-the-Art Manufacturing, GeneMedi helps accelerate multiple modalities of Macro-Molecule Discovery & Development (M-M D&D), and scalable manufacturing including antibodies, recombinant protein, and multiple types of gene therapeutic vectors and delivery vehicles (AAV, VLP, etc.).

GMers believe that interdisciplinary innovation will revolute the global bio-medicine in both therapeutics and diagnostics.

GeneMedi Diagnostics Unit (GDU)

Combined insight of novel biomarkers-ligands science with brilliant capability of Macro-Molecule Discovery & Development (M-M D&D) technology, GDU helps global diagnostic partners in high quality of raw material discovery, development, and application.

GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.

GeneMedi BGM-XTM Innovative Engine



With years of modalities discovery insight and expertise in the pharmaceutical industry, GeneMedi has developed innovative platforms BGM-XTM for big data-driven modalities of biologics and gene therapy scientific discovery and industrial development.

- 1. VLPxTM-Platform for Types of Virus-like particles development
- 2. TP-MaxTM-Plaform for Multi-Transmembrane Protein antibody discovery
- 3. Anti-OptTM-Platform for antibody humanization, evolution and maturation
- 4. G-NEXTTM-Platform for Novel AAV discovery



SOCAIL MEDIA





Email: support@genemedi.net | sales@genemedi.net **Telephone:** +86-21-50478399 **Fax:** 86-21-50478399

Address: 6th Floor, Building No.2, KangXin Road 3377, Shanghai, China

Leave your message, we will reply in 1 day: www.genemedi.net/contact